Find policies, billing codes, payers, states, and providers
Metabolite Markers of Thiopurines Testing
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines when phenotypic TPMT testing and monitoring of thiopurine metabolite markers (e.g., 6-TGN, 6-MMP/6-MMRP) are covered for members, and when metabolite testing is not covered.
No material clinical or coverage changes in this revision.
Coverage Criteria
Covered indications
Covered when ANY of the following are met
One-time test when performed prior to initiating therapy.
As clinically indicated.
As clinically indicated.
Not medically necessary / Not covered
When testing is recommended
Testing is recommended in the following clinical scenarios per cited guidelines:
Sourced from NCCN, NASPGHAN, AGA, CPIC, ECCO/ESPGHAN.
Phenotypic TPMT testing and thiopurine metabolite analysis are not covered for situations other than those explicitly listed in the covered indications. The policy permits a one-time TPMT phenotypic analysis prior to initiating azathioprine, 6-mercaptopurine, or 6-thioguanine and TPMT testing for individuals on thiopurines with abnormal CBC not responsive to dose reduction; outside those listed uses, phenotypic TPMT testing and metabolite analysis do not meet criteria.
The American Gastroenterological Association (AGA) guidance advises against routine thiopurine metabolite monitoring in patients with quiescent inflammatory bowel disease. The AGA recommends reactive monitoring for adults with active IBD or adverse effects thought to be due to thiopurine toxicity, but suggests against routine metabolite surveillance in asymptomatic, stable patients on thiopurines.
No additional explicit exclusions are stated in the provided excerpt of this policy.
For all other situations not addressed in the covered indications, phenotypic analysis of TPMT does not meet criteria. The policy language specifies that TPMT phenotypic testing is covered only for the listed scenarios and otherwise is not supported.
Consensus guidance from NASPGHAN states that routine and repetitive metabolite testing has little or no role in patients who are clinically well and taking an acceptable thiopurine dose. Metabolite testing is instead described as useful in reactive contexts such as active disease, toxicity, nonresponse, or to assess adherence.
No explicit statements labeling specific tests or indications as "not medically necessary" are provided in the excerpt beyond the general not-meeting-criteria language already specified.
Covered Indications (detailed)
Pre-treatment TPMT phenotypic testing prior to initiating AZA, 6-MP, or 6-TG
Document indication and relevant baseline labs (e.g., CBC, LFTs) when submitting.
TPMT phenotypic testing for individuals on thiopurine therapy with abnormal CBC not responsive to dose reduction
Submit documentation of CBC results and dose-adjustment attempts.
Monitoring thiopurine metabolites in IBD for suspected toxicity or lack of response
Reactive monitoring recommended; routine monitoring in quiescent IBD is not supported by AGA.
Monitoring thiopurine metabolites in ALL for lack of myelosuppression or intolerance
Consider TPMT/NUDT15 genotyping per NCCN guidance.
Pre-treatment assessment to identify TPMT/NUDT15 no-function alleles or low enzyme activity; evaluation of toxicity (myelotoxicity, elevated transaminases); assessment of nonresponse or suspected nonadherence; optimization of dosing in inadequate responders.
Guideline-based scenarios drawn from NCCN, NASPGHAN, CPIC, and ECCO/ESPGHAN.
References support testing in inflammatory bowel disease (Crohn's disease, ulcerative colitis), pediatric IBD, and acute lymphoblastic leukemia.
See policy references for full citations.
Coding and Laboratory Values
Billing, coding and lab validation — use specified CPT codes and CLIA-validated LDTs
Use the listed CPT/HCPCS procedure codes when billing for thiopurine metabolite and TPMT testing, ensure tests performed as laboratory-developed tests are validated under CLIA high-complexity rules, and be aware applicable Medicare/Medicaid LCDs or NCDs may govern coverage determinations.
- Bill using CPT codes 80299, 82657, and 84433 for thiopurine metabolite and TPMT-related testing.
- Laboratories performing in-house LDTs must validate those tests and comply with CLIA '88 high-complexity regulations.
- Coverage and authorization may still be governed by applicable government policies (e.g., LCDs or NCDs).
Frequency Limits
Provider Actions and Requirements
Confirm authorization and medical necessity
Services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and the member's state of residence; coverage depends on the member's benefit at time of request.
- Confirm benefit coverage and medical necessity before ordering.
- Follow applicable state and federal Medicare/Medicaid specifications as noted in policy.
Prior authorization not specified
No prior authorization requirement is specified in this policy excerpt.
No step therapy—use reactive testing per guidelines
The policy does not define step therapy rules; clinical guidance recommends testing in reactive scenarios (nonresponse, suspected toxicity) rather than routine proactive monitoring.
- Testing is recommended for nonresponse, suspected toxicity, suspected nonadherence, or to optimize dosing—not for routine surveillance in stable patients.
Provide clinical indication and relevant labs
Submit supporting clinical documentation showing the indication for testing (for example: IBD with nonresponse or suspected toxicity, ALL with lack of myelosuppression or intolerance, or pre‑treatment TPMT testing) and include relevant lab results such as CBC and LFTs when applicable.
- Include documentation of clinical signs (e.g., persistent fever, weight loss, bloody diarrhea) or laboratory abnormalities (CBC, transaminases) that justify metabolite or TPMT testing.
Include evidence references when needed
The policy cites evidence‑based scientific references (guidelines and studies) that can be used to support clinical justification for testing.
- See the policy's Evidence‑based Scientific References section for cited studies and guideline sources.
Risk of denial for improper coding or documentation
Claims may be denied or payments recouped if coding/billing guidelines or current reimbursement policies are not followed and documentation is inaccurate.
- Ensure coding follows industry standards (CPT, HCPCS, ICD‑10, CMS guidance) and documentation accurately reflects medical necessity.
Government policy takes precedence when applicable
If this policy conflicts with applicable government policies (e.g., LCDs or NCDs), the government policy will be used to make coverage determinations and may override this policy.
- Check Medicare/Medicaid LCDs and NCDs for members covered under government programs prior to ordering or billing.
Ordering Requirements
Ensure benefit coverage and accurate documentation before ordering
Services must meet authorization and medical necessity guidelines and be supported by benefit coverage at the time of request; providers must submit accurate documentation and appropriate coding.
- Confirm member benefits and medical necessity before ordering.
- Provide accurate clinical documentation and use appropriate codes.
No specific ordering‑provider restrictions; typically ordered by treating specialists
The policy does not impose explicit ordering‑provider restrictions; clinical practice implies testing is ordered by treating specialists such as gastroenterology, hematology/oncology, or pediatric specialists when clinically indicated.
- Order tests in the context of specialist care when appropriate (e.g., IBD or ALL management).
No ordering‑provider restrictions specified
No ordering provider restrictions are specified in this policy excerpt.
Not Covered / Limitations
Analysis of thiopurine metabolite markers and TPMT phenotypic testing for indications not listed among the covered indications does not meet criteria. The policy restricts coverage to the enumerated clinical scenarios and does not support these tests for unlisted uses.
Because the AGA recommends against routine metabolite monitoring in patients with quiescent IBD, routine or proactive metabolite surveillance for all unselected patients in remission is not supported by these guideline recommendations and therefore is not a covered use.
The excerpt does not list additional tests or specific clinical indications that are explicitly excluded beyond the general statements that unlisted uses do not meet criteria.
Background
Thiopurines (azathioprine, 6-mercaptopurine, thioguanine) are commonly used for autoimmune disorders, prevention of transplant rejection, and treatment of acute lymphoblastic leukemia. Efficacy and toxicity are related to downstream metabolites such as 6-TGN and 6-MMP, and TPMT enzyme activity and genetic variants influence metabolism and risk of myelotoxicity and hepatotoxicity.
Definitions
Revision History
Original documentation of the policy was prepared and governance approved.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.